title: The future of small molecule inhibitors in lymphoma.
abstract: For the many patients with lymphoma that has relapsed after and/or has become refractory to existing treatments, the development of novel therapeutics is imperative. Investigation into intracellular processes that are dysregulated during lymphomagenesis has uncovered several new potential targets for anticancer agents. Although monoclonal antibodies and other immunotherapeutics have led to dramatic advances in the treatment of patients with lymphoma, the parallel development of small molecule inhibitors has been equally exciting. These agents, whose small size allows direct entry into tumor cells, can target distinct proteins or complexes, thereby disrupting molecular processes on which neoplastic cells depend for survival and growth. This review surveys the published literature on many of these new targeted molecules, focusing on some of the most promising agents for which phase 2 data currently exist. It also explores the potential for incorporating these agents into broader multidrug regimens.
authors.affiliation: Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. gerecitj@mskcc.org
authors.forename: John
authors.initials: J
authors.lastname: Gerecitano
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D055808:Drug Discovery / Q000639:trends; D005544:Forecasting; D006655:Histone Deacetylases; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D009842:Oligopeptides / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D011719:Pyrazines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D009842:Oligopeptides; D011480:Protease Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D011719:Pyrazines; D000069286:Bortezomib; C524865:carfilzomib; D006655:Histone Deacetylases
references.citation: Curr Opin Drug Discov Devel. 2005 Jul;8(4):431-6
references.pmid: 16022179
references.citation: Blood. 2008 Feb 15;111(4):2230-7
references.pmid: 18006696
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7
references.pmid: 18040043
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5165-73
references.pmid: 16951235
references.citation: Curr Opin Oncol. 2003 Nov;15(6):419-24
references.pmid: 14624223
references.citation: J Clin Oncol. 2005 Feb 1;23(4):676-84
references.pmid: 15613699
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7697-702
references.pmid: 16186597
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4500-10
references.pmid: 18628465
references.citation: Leuk Lymphoma. 2007 Jul;48(7):1313-9
references.pmid: 17613759
references.citation: Ann Oncol. 2007 Jan;18(1):116-121
references.pmid: 16971665
references.citation: J Clin Oncol. 2007 Mar 20;25(9):1114-20
references.pmid: 17296974
references.citation: J Clin Oncol. 2007 Jul 20;25(21):3109-15
references.pmid: 17577020
references.citation: Oncologist. 2007 Jun;12(6):664-89
references.pmid: 17602058
references.citation: Br J Haematol. 2009 Sep;146(6):652-5
references.pmid: 19624539
references.citation: J Clin Oncol. 2006 Jan 1;24(1):166-73
references.pmid: 16330674
references.citation: Expert Opin Investig Drugs. 2008 Jun;17(6):879-95
references.pmid: 18491989
references.citation: Blood. 2009 Feb 19;113(8):1723-9
references.pmid: 19064730
references.citation: Blood. 2009 May 7;113(19):4667-76
references.pmid: 19050304
references.citation: Br J Haematol. 2010 Oct;151(1):47-53
references.pmid: 20735402
references.citation: Cancer Res. 2007 Jul 1;67(13):6383-91
references.pmid: 17616698
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5347-56
references.pmid: 15983389
references.citation: Blood. 2008 Apr 1;111(7):3322-30
references.pmid: 18362212
references.citation: Nature. 2009 Apr 9;458(7239):732-6
references.pmid: 19360080
references.citation: Oncologist. 2006 Jan;11(1):51-61
references.pmid: 16401713
references.citation: J Clin Oncol. 2002 Nov 15;20(22):4420-7
references.pmid: 12431963
references.citation: J Clin Oncol. 2000 May;18(9):1812-23
references.pmid: 10784621
references.citation: Br J Cancer. 2006 Oct 23;95(8):961-5
references.pmid: 17047643
references.citation: Expert Rev Mol Med. 2008 Feb 04;10:e4
references.pmid: 18241520
references.citation: J Clin Oncol. 2005 Feb 1;23(4):667-75
references.pmid: 15613697
references.citation: Blood. 2009 Apr 2;113(14):3154-60
references.pmid: 19096013
references.citation: Blood. 2007 Jan 1;109(1):31-9
references.pmid: 16960145
references.citation: Nat Rev Cancer. 2008 Feb;8(2):121-32
references.pmid: 18202696
references.citation: Ann Oncol. 2009 Mar;20(3):520-5
references.pmid: 19074748
references.citation: Blood. 2009 Jan 8;113(2):299-305
references.pmid: 18931344
references.citation: Expert Rev Anticancer Ther. 2006 Jan;6(1):109-20
references.pmid: 16375648
references.citation: Expert Rev Anticancer Ther. 2008 Mar;8(3):413-32
references.pmid: 18366289